Patenting Prospects for Cell-Based Therapies

Cell-based therapies are moving medical treatments forward, but intellectual property uncertainties may delay progress.

Treatment using cell-based therapies involves significant investment and, therefore, can be expected to have concomitantly significant costs to patients and their insurers. Accordingly, patent exclusivity will be important to defray high development and regulatory compliance costs.

The nature of such therapies, and recent patent law trends regarding natural products and methods relating to the practice of medicine, suggest these therapies may not be given the type of robust patent protection conventionally available for small-molecule drugs. The author discusses the impact of patent considerations for cell-based therapies.

Download the

BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook

.

Article Details

BioPharm Internationalâ¨eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 19–22

Citation

When referring to this article, please cite it as K. Noonan, " Patenting Prospects for Cell-Based Therapies," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).

Articles in this issue

over 8 years ago

Article

Harvest of Human Mesenchymal Stem Cells from Microcarriers

over 8 years ago

Article

Affinity Chromatography Accelerates Viral Vector Purification for Gene Therapies

over 8 years ago

Article

End-to-End Cell Therapy Automation: An Immunotherapy Case Study

over 8 years ago

Article

Optimizing a Unique Cancer Vaccine for Intradermal Delivery

over 8 years ago

Article

Accelerating Genetic Medicine R&D Using Microfluidics

over 8 years ago

Article

Overcoming Hurdles in Emerging Therapy Development

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!